[go: up one dir, main page]

WO2025006973A3 - Méthodes de traitement d'événements indésirables liés à l'immunité - Google Patents

Méthodes de traitement d'événements indésirables liés à l'immunité Download PDF

Info

Publication number
WO2025006973A3
WO2025006973A3 PCT/US2024/036139 US2024036139W WO2025006973A3 WO 2025006973 A3 WO2025006973 A3 WO 2025006973A3 US 2024036139 W US2024036139 W US 2024036139W WO 2025006973 A3 WO2025006973 A3 WO 2025006973A3
Authority
WO
WIPO (PCT)
Prior art keywords
ici
therapy
methods
subject
adverse events
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/036139
Other languages
English (en)
Other versions
WO2025006973A2 (fr
Inventor
Jamie LIN
Cassian Yee
James P. Long
Shailbala SINGH
Yanlan DONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of WO2025006973A2 publication Critical patent/WO2025006973A2/fr
Publication of WO2025006973A3 publication Critical patent/WO2025006973A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente divulgation propose des méthodes améliorées de traitement de patients qui ont reçu une thérapie par inhibiteur de point de contrôle immunitaire (IPCI) et sur la base de la découverte selon laquelle des biomarqueurs peuvent prédire si un sujet subissant des symptômes indésirables et subissant une thérapie par IPCI développe un irAE dû à la thérapie par IPCI ou en raison d'une pathologie non directement liée à la thérapie par IPCI. Les méthodes comprennent un procédé d'évaluation d'un sujet comprenant la mesure du niveau d'un ou de plusieurs biomarqueurs dans un échantillon biologique provenant du sujet, le ou les biomarqueurs étant un ou plusieurs parmi IL5, CD274, TNFSF4, FAS, IL20, TSLP, TNFSF15, CCL1, IL6, TNF, CLEC4A, NCR1, FGF19, IL5RA, MUC16, CCL3, VCAM1, EPO, IFNL1, MMP3, IL9, IL16, IL36A, FLT1, IL18, IL12RB1, KITLG, LTF, CCL18, LCN2, CXCL13, S100A8, CXCL9, CD79A, CCR7, CXCL1, C3, TREM1, IL7R, CD19, LTB, MS4A1, SAA1, CXCL10, C1QB, TNFRSF17, CTLA4, CXCL6, CD27, CD38, CXCL11, CD163, FCGR3A, ITGAX, CD7, C1QA, RUNX3, SLAMF7, IRF4, SELL, ZAP70, CD48, SIGLEC1, PDCD1, IL2RB, JAK3, CTSS, CSF2RB, IL2RG, ISG20, EBI3, C2, ITGAL, CCR5, IDO1, LCP1, CD5, CD6, SH2D1A, CYBB, CCL5, IL10RA, VEGFC, IL13RA2, IL36G, MMP9, EGF, CTF1, CHI3L1, IL1R1, TNFRSF8, SPP1, IL15RA, TNFRSF1B, TNFRSF18, TNFRSF1A, CX3CL1, CD40, IL17A, TNFRSF14, CXADR, TNFRSF9, TNFRSF11A, TNFSF11, IL2RA, MDK, IL18BP, LTBR, SLURP1, CSF1 et IL33.
PCT/US2024/036139 2023-06-29 2024-06-28 Méthodes de traitement d'événements indésirables liés à l'immunité Pending WO2025006973A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363524033P 2023-06-29 2023-06-29
US63/524,033 2023-06-29
US202363545807P 2023-10-26 2023-10-26
US63/545,807 2023-10-26

Publications (2)

Publication Number Publication Date
WO2025006973A2 WO2025006973A2 (fr) 2025-01-02
WO2025006973A3 true WO2025006973A3 (fr) 2025-05-08

Family

ID=93940001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/036139 Pending WO2025006973A2 (fr) 2023-06-29 2024-06-28 Méthodes de traitement d'événements indésirables liés à l'immunité

Country Status (1)

Country Link
WO (1) WO2025006973A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100086547A1 (en) * 2007-04-30 2010-04-08 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
WO2012018538A2 (fr) * 2010-07-26 2012-02-09 Schering Corporation Bio-essais pour la détermination de la modulation de pd-1
US20210380699A1 (en) * 2016-06-20 2021-12-09 Kymab Limited Anti-pd-l1 antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100086547A1 (en) * 2007-04-30 2010-04-08 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
WO2012018538A2 (fr) * 2010-07-26 2012-02-09 Schering Corporation Bio-essais pour la détermination de la modulation de pd-1
US20210380699A1 (en) * 2016-06-20 2021-12-09 Kymab Limited Anti-pd-l1 antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUPTA SHRUTI, GUDSOORKAR PRAKASH, JHAVERI KENAR D.: "Acute Kidney Injury in Critically Ill Patients with Cancer", CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 17, no. 9, 1 September 2022 (2022-09-01), pages 1385 - 1398, XP093311908, ISSN: 1555-9041, DOI: 10.2215/CJN.15681221 *
MILNER T., REILLY L., NAUSCH N., MIDZI N., MDULUZA T., MAIZELS R., MUTAPI F.: "Circulating cytokine levels and antibody responses to human Schistosoma haematobium : IL‐5 and IL‐10 levels depend upon age and infection status", PARASITE IMMUNOLOGY, vol. 32, no. 11-12, 1 November 2010 (2010-11-01), GB , pages 710 - 721, XP093311907, ISSN: 0141-9838, DOI: 10.1111/j.1365-3024.2010.01235.x *
MOLEDINA DENNIS G., WILSON F. PERRY, POBER JORDAN S., PERAZELLA MARK A., SINGH NIKHIL, LUCIANO RANDY L., OBEID WASSIM, LIN HAIQUN,: "Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis", JCI INSIGHT, vol. 4, no. 10, 16 May 2019 (2019-05-16), pages 1 - 14, XP093311902, ISSN: 2379-3708, DOI: 10.1172/jci.insight.127456 *

Also Published As

Publication number Publication date
WO2025006973A2 (fr) 2025-01-02

Similar Documents

Publication Publication Date Title
Pattni et al. Fibroblast growth factor 19 and 7α-hydroxy-4-cholesten-3-one in the diagnosis of patients with possible bile acid diarrhea
Pérez-Gutiérrez et al. Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population
Zhang et al. Bronchoalveolar bile acid and inflammatory markers to identify high-risk lung transplant recipients with reflux and microaspiration
Scott et al. Short-term prognosis in early relapsing-remitting multiple sclerosis
Aschman et al. Post-COVID exercise intolerance is associated with capillary alterations and immune dysregulations in skeletal muscles
Zeineddine et al. Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage
Doolette et al. Sample size requirement for comparison of decompression outcomes using ultrasonically detected venous gas emboli (VGE): power calculations using Monte Carlo resampling from real data
WO2025006973A3 (fr) Méthodes de traitement d'événements indésirables liés à l'immunité
Mroz et al. Beryllium lymphocyte proliferation test surveillance identifies clinically significant beryllium disease
Marchegiani et al. The actual prevalence of symptoms in pancreatic cystic neoplasms: a prospective propensity matched cohort analysis
Koen et al. From humans to rats and back again: Bridging the divide between human and animal studies of recognition memory with receiver operating characteristics
Nethercott Sensitivity and specificity of patch tests
Irem et al. Copeptin levels in carbon monoxide poisoning
Razvi et al. Changes in thyroid function and autoimmunity in older individuals: longitudinal analysis of the Whickham cohort
EP1725876B1 (fr) Procede permettant de predire l'etat de la muqueuse gastrique
Hewage et al. Prevalence of subclinical hypothyroidism in a non-diabetic young female population and its impact on diabetes and cardiometabolic risk
Sassi et al. Conjoint analysis of preferences for cardiac risk assessment in primary care
Zhao et al. The CoNUT score predicts the length of hospital stay and the risk of long CoVID.
Temiz Karadag et al. The potential of semi-quantitative and quantitative methods in predicting progression in rheumatoid arthritis-associated interstitial lung disease
CN115684604A (zh) 用于预测帕金森疾病进展的标记物及其用途
US20220065877A1 (en) Use of GDF-15 in the Diagnosis and Treatment of Frailty and Conditions Associated with Altered Physiological Reserve, Physical Fitness and Exercise Capacity
Sun et al. Monocyte to high-density lipoprotein cholesterol ratio as a predictor of the activity of thyroid-associated ophthalmopathy
Hytting et al. Prevalence of abnormal thyroid hormone levels in acute new-onset atrial fibrillation
Parrey et al. Correlation between Quality of Life and Erythrocyte Sedimentation Rate with Disease Activity in Rheumatoid Arthritis
US20240044826A1 (en) Metabolic vulnerability analyzed by nmr